Antibiotic Stewardship for Total Joint Arthroplasty in 2020
| Autor: | Antonia F. Chen, Jason S Lipof, Thomas G. Myers, Benjamin F. Ricciardi |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Prosthesis-Related Infections Joint arthroplasty medicine.drug_class medicine.medical_treatment Antibiotics MEDLINE Periprosthetic Antimicrobial Stewardship 03 medical and health sciences 0302 clinical medicine Humans Medicine Orthopedics and Sports Medicine Arthroplasty Replacement Intensive care medicine 030222 orthopedics business.industry 030229 sport sciences Perioperative Antibiotic Prophylaxis Arthroplasty Anti-Bacterial Agents Prosthesis Failure Antibiotic delivery Antibiotic Stewardship Surgery business |
| Zdroj: | Journal of the American Academy of Orthopaedic Surgeons. 28:e793-e802 |
| ISSN: | 1940-5480 1067-151X |
| Popis: | Projections indicate an increase in primary and revision total joint arthroplasties (TJAs). Periprosthetic joint infections (PJIs) are one of the most common and devastating causes of failure after TJA. Perioperative administration of systemic and/or local antibiotics is used for both prophylaxis and treatment of PJI. Antibiotic stewardship is a term that has been met with clinical acceptance and success in other specialties of medicine. Identifying antibiotic best practice use in the fight against PJI is limited by studies that are extremely heterogeneous in their design. Variations in studies include antibiotic selection and duration, surgical débridement steps, type of antibiotic delivery (intra-articular, local, intravenous, and prolonged oral), mix of primary and revision surgery cohorts, both hip and knee cohorts, infecting organisms, and definitions of treatment success/failure. This review highlights the current challenges of antibiotic stewardship in TJA. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|